Current and emerging modalities for detection of cardiotoxicity in cardio-oncology

Papers of special note have been highlighted as: • of interest

References

• 1 Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970–2002. JAMA 294(10), 1255–1259 (2005).
  Medline CASGoogle Scholar
• 2 Jemal A, Ward E, Thun M. Declining death rates reflect progress against cancer. PLoS ONE 5(3), e9584 (2010).
  MedlineGoogle Scholar
• 3 Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from population-based data. J. Natl Cancer Inst. 102(20), 1584–1598 (2010).
  MedlineGoogle Scholar
• 4 Siegel R, Desantis C, Virgo K et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 62(4), 220–241 (2012).
  MedlineGoogle Scholar
• 5 Chapman JA, Meng D, Shepherd L et al. Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. J. Natl Cancer Inst. 100(4), 252–260 (2008).
  MedlineGoogle Scholar
• 6 Hanrahan EO, Gonzalez-Angulo AM, Giordano SH et al. Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma. J. Clin. Oncol. 25(31), 4952–4960 (2007).
  MedlineGoogle Scholar
• 7 Lloyd-Jones DM, Leip EP, Larson MG et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 113(6), 791–798 (2006).
  MedlineGoogle Scholar
• 8 Schairer C, Mink PJ, Carroll L, Devesa SS. Probabilities of death from breast cancer and other causes among female breast cancer patients. J. Natl Cancer Inst. 96(17), 1311–1321 (2004).
  MedlineGoogle Scholar
• 9 Patnaik JL, Byers T, Diguiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res. 13(3), R64 (2011).
  MedlineGoogle Scholar
• 10 Colzani E, Liljegren A, Johansson AL et al. Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. J. Clin. Oncol. 29(30), 4014–4021 (2011).
  MedlineGoogle Scholar
• 11 Jones LW, Haykowsky MJ, Swartz JJ, Douglas PS, Mackey JR. Early breast cancer therapy and cardiovascular injury. J. Am. Coll. Cardiol. 50(15), 1435–1441 (2007).
  MedlineGoogle Scholar
• 12 Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol. 53(24), 2231–2247 (2009).
  Medline CASGoogle Scholar
• 13 Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370(9604), 2011–2019 (2007).
  Medline CASGoogle Scholar
• 14 Hall PS, Harshman LC, Srinivas S, Witteles RM. The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. JACC Heart Fail 1(1), 72–78 (2013).
  MedlineGoogle Scholar
• 15 Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91(5), 710–717 (1979).
  Medline CASGoogle Scholar
• 16 Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97(11), 2869–2879 (2003).
  Medline CASGoogle Scholar
• 17 Perez EA, Suman VJ, Davidson NE et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J. Clin. Oncol. 22(18), 3700–3704 (2004).
  Medline CASGoogle Scholar
• 18 Meinardi MT, Van Veldhuisen DJ, Gietema JA et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J. Clin. Oncol. 19(10), 2746–2753 (2001).
  Medline CASGoogle Scholar
• 19 Mackey JR, Martin M, Pienkowski T et al. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10 year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 14(1), 72–80 (2013).
  Medline CASGoogle Scholar
• 20 Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br. J. Haematol. 131(5), 561–578 (2005).
  Medline CASGoogle Scholar
• 21 Schmidinger M, Zielinski CC, Vogl UM et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 26(32), 5204–5212 (2008).
  MedlineGoogle Scholar
• 22 Tocchetti CG, Ragone G, Coppola C et al. Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge. Eur. J. Heart Fail. 14(2), 130–137 (2012).
  Medline CASGoogle Scholar
• 23 Force T, Kolaja KL. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat. Rev. Drug Discov. 10(2), 111–126 (2011).
  Medline CASGoogle Scholar
• 24 Ky B, Vejpongsa P, Yeh ET, Force T, Moslehi JJ. Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ. Res. 113(6), 754–764 (2013).• Outlines the proposed mechanisms of cardiotoxicity of common and newer anticancer agents.
  Medline CASGoogle Scholar
• 25 Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J. Clin. Oncol. 23(31), 7811–7819 (2005).
  Medline CASGoogle Scholar
• 26 Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J. Clin. Oncol. 22(2), 322–329 (2004).
  Medline CASGoogle Scholar
• 27 Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ. Res. 106(1), 21–34 (2010).
  Medline CASGoogle Scholar
• 28 Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J. Clin. Oncol. 25(23), 3525–3533 (2007).
  Medline CASGoogle Scholar
• 29 Common Terminology Criteria for Adverse Events V4.03 (CTCAE). http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
  Google Scholar
• 30 Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. 20(5), 1215–1221 (2002).
  Medline CASGoogle Scholar
• 31 Yancy CW, Jessup M, Bozkurt B et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 62(16), e147–E239 (2013).
  MedlineGoogle Scholar
• 32 Ammar KA, Jacobsen SJ, Mahoney DW et al. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation 115(12), 1563–1570 (2007).
  MedlineGoogle Scholar
• 33 Cardinale D, Colombo A, Lamantia G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J. Am. Coll. Cardiol. 55(3), 213–220 (2010).• Demonstrates the importance of early detection of cardiotoxicity as an opportunity for intervention and reversibility of cardiotoxicity.
  Medline CASGoogle Scholar
• 34 Lenihan DJ, Sawyer DB. Heart disease in cancer patients: a burgeoning field where optimizing patient care is requiring interdisciplinary collaborations. Heart Fail. Clin. 7(3), xxi–xxiii (2011).
  MedlineGoogle Scholar
• 35 Plana JC, Galderisi M, Barac A et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Standardizecardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Standardizecardiogr. 27(9), 911–939 (2014).
  MedlineGoogle Scholar
• 36 Khouri MG, Douglas PS, Mackey JR et al. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation 126(23), 2749–2763 (2012).
  MedlineGoogle Scholar
• 37 Curigliano G, Cardinale D, Suter T et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann. Oncol. 23(Suppl. 7), vii155–vii166 (2012).
  MedlineGoogle Scholar
• 38 Verma S, Ewer MS. Is cardiotoxicity being adequately assessed in current trials of cytotoxic and targeted agents in breast cancer. Ann. Oncol. 22(5), 1011–1018 (2011).
  Medline CASGoogle Scholar
• 39 Bellenger NG, Burgess MI, Ray SG et al. Comparison of left ventricular ejection fraction and volumes in heart failure by standardizecardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable. Eur. Heart J. 21(16), 1387–1396 (2000).
  Medline CASGoogle Scholar
• 40 Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground. J. Clin. Oncol. 26(8), 1201–1203 (2008).
  MedlineGoogle Scholar
• 41 Trastuzumab (Herceptin^®), package insert. Genentech, Inc., CA, USA.
  Google Scholar
• 42 Romond EH, Jeong JH, Rastogi P et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 30(31), 3792–3799 (2012).• Demonstrates the prognostic value of baseline left ventricular ejection fraction (LVEF) in predicting longer-term cardiotoxicity.
  Medline CASGoogle Scholar
• 43 Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673–1684 (2005).
  Medline CASGoogle Scholar
• 44 Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365(14), 1273–1283 (2011).
  Medline CASGoogle Scholar
• 45 Schmitz KH, Prosnitz RG, Schwartz AL, Carver JR. Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors. Cancer 118(8 Suppl.), 2270–2276 (2012).
  MedlineGoogle Scholar
• 46 Ewer MS, Ali MK, Mackay B et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin. J. Clin. Oncol. 2(2), 112–117 (1984).
  Medline CASGoogle Scholar
• 47 Delgado V, Mollema SA, Ypenburg C et al. Relation between global left ventricular longitudinal strain assessed with novel automated function imaging and biplane left ventricular ejection fraction in patients with coronary artery disease. J. Am. Soc. Echocardiogr. 21(11), 1244–1250 (2008).
  MedlineGoogle Scholar
• 48 Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111(21), 2837–2849 (2005).
  MedlineGoogle Scholar
• 49 Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J. Clin. Oncol. 23(34), 8597–8605 (2005).
  MedlineGoogle Scholar
• 50 Jones LW, Eves ND, Haykowsky M, Freedland SJ, Mackey JR. Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol. 10(6), 598–605 (2009).
  MedlineGoogle Scholar
• 51 Lakoski SG, Eves ND, Douglas PS, Jones LW. Exercise rehabilitation in patients with cancer. Nat. Rev. Clin. Oncol. 9(5), 288–296 (2012).
  MedlineGoogle Scholar
• 52 Chaosuwannakit N, D'agostino R Jr, Hamilton CA et al. Aortic stiffness increases upon receipt of anthracycline chemotherapy. J. Clin. Oncol. 28(1), 166–172 (2010).
  Medline CASGoogle Scholar
• 53 Beckman JA, Thakore A, Kalinowski BH, Harris JR, Creager MA. Radiation therapy impairs endothelium-dependent vasodilation in humans. J. Am. Coll. Cardiol. 37(3), 761–765 (2001).
  Medline CASGoogle Scholar
• 54 Koelwyn GJ, Khouri M, Mackey JR, Douglas PS, Jones LW. Running on empty: cardiovascular reserve capacity and late effects of therapy in cancer survivorship. J. Clin. Oncol. 30(36), 4458–4461 (2012).
  MedlineGoogle Scholar
• 55 Walker J, Bhullar N, Fallah-Rad N et al. Role of three-dimensional standardizecardiography in breast cancer: comparison with two-dimensional standardizecardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J. Clin. Oncol. 28(21), 3429–3436 (2010).
  MedlineGoogle Scholar
• 56 Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popovic ZB, Marwick TH. Reproducibility of standardizecardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J. Am. Coll. Cardiol. 61(1), 77–84 (2013).• Reports the temporal variability of LVEF assessments by 2D echocardiography in cancer patients being serially monitored during therapy.
  MedlineGoogle Scholar
• 57 Cranney GB, Lotan CS, Dean L, Baxley W, Bouchard A, Pohost GM. Left ventricular volume measurement using cardiac axis nuclear magnetic resonance imaging. Validation by calibrated ventricular angiography. Circulation 82(1), 154–163 (1990).
  Medline CASGoogle Scholar
• 58 Grothues F, Smith GC, Moon JC et al. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional standardizecardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am. J. Cardiol. 90(1), 29–34 (2002).
  MedlineGoogle Scholar
• 59 Sandner TA, Houck P, Runge VM et al. Accuracy of accelerated cine MR imaging at 3 Tesla in longitudinal follow-up of cardiac function. Eur. Radiol. 18(10), 2095–2101 (2008).
  MedlineGoogle Scholar
• 60 Mcmurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 33(14), 1787–1847 (2012).
  MedlineGoogle Scholar
• 61 Kalam K, Otahal P, Marwick TH. Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction. Heart 100(21), 1673–1680 (2014).
  MedlineGoogle Scholar
• 62 Watts RG, George M, Johnson WH Jr. Pretreatment and routine standardizecardiogram monitoring during chemotherapy for anthracycline-induced cardiotoxicity rarely identifies significant cardiac dysfunction or alters treatment decisions: a 5-year review at a single pediatric oncology center. Cancer 118(7), 1919–1924 (2012).
  MedlineGoogle Scholar
• 63 Carver JR, Shapiro CL, Ng A et al. American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J. Clin. Oncol. 25(25), 3991–4008 (2007).
  Medline CASGoogle Scholar
• 64 Gorcsan J 3rd, Tanaka H. Standardizecardiographic assessment of myocardial strain. J. Am. Coll. Cardiol. 58(14), 1401–1413 (2011).
  MedlineGoogle Scholar
• 65 Sengupta PP, Tajik AJ, Chandrasekaran K, Khandheria BK. Twist mechanics of the left ventricle: principles and application. JACC Cardiovasc. Imaging 1(3), 366–376 (2008).
  MedlineGoogle Scholar
• 66 Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by standardizecardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J. Am. Coll. Cardiol. 63(25 Pt A), 2751–2768 (2014).
  MedlineGoogle Scholar
• 67 Ganame J, Claus P, Uyttebroeck A et al. Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients. J. Am. Soc. Echocardiogr. 20(12), 1351–1358 (2007).
  MedlineGoogle Scholar
• 68 Jurcut R, Wildiers H, Ganame J et al. Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer. J. Am. Soc. Echocardiogr. 21(12), 1283–1289 (2008).
  MedlineGoogle Scholar
• 69 Hare JL, Brown JK, Leano R, Jenkins C, Woodward N, Marwick TH. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. Am. Heart J. 158(2), 294–301 (2009).
  Medline CASGoogle Scholar
• 70 Mercuro G, Cadeddu C, Piras A et al. Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler standardizecardiography: correlation with inflammatory and oxidative stress markers. Oncologist 12(9), 1124–1133 (2007).
  Medline CASGoogle Scholar
• 71 Sawaya H, Sebag IA, Plana JC et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am. J. Cardiol. 107(9), 1375–1380 (2011).
  Medline CASGoogle Scholar
• 72 Sawaya H, Sebag IA, Plana JC et al. Assessment of standardizecardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ. Cardiovasc. Imaging 5(5), 596–603 (2012).• The largest study thus far to assess the prognostic value of strain and blood-based biomarkers for predicting cardiotoxicity.
  MedlineGoogle Scholar
• 73 Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J. Am. Soc. Echocardiogr. 26(5), 493–498 (2013).
  MedlineGoogle Scholar
• 74 Motoki H, Koyama J, Nakazawa H et al. Torsion analysis in the early detection of anthracycline-mediated cardiomyopathy. Eur. Heart J. Cardiovasc. Imaging 13(1), 95–103 (2012).
  MedlineGoogle Scholar
• 75 Cheung YF, Li SN, Chan GC, Wong SJ, Ha SY. Left ventricular twisting and untwisting motion in childhood cancer survivors. Echocardiography 28(7), 738–745 (2011).
  MedlineGoogle Scholar
• 76 Yu HK, Yu W, Cheuk DK, Wong SJ, Chan GC, Cheung YF. New three-dimensional speckle-tracking echocardiography identifies global impairment of left ventricular mechanics with a high sensitivity in childhood cancer survivors. J. Am. Soc. Echocardiogr. 26(8), 846–852 (2013).
  MedlineGoogle Scholar
• 77 Risum N, Ali S, Olsen NT et al. Variability of global left ventricular deformation analysis using vendor dependent and independent two-dimensional speckle-tracking software in adults. J. Am. Soc. Echocardiogr. 25(11), 1195–1203 (2012).
  MedlineGoogle Scholar
• 78 Wassmuth R, Lentzsch S, Erdbruegger U et al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study. Am. Heart J. 141(6), 1007–1013 (2001).
  Medline CASGoogle Scholar
• 79 Isner JM, Ferrans VJ, Cohen SR et al. Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy. Am. J. Cardiol. 51(7), 1167–1174 (1983).
  Medline CASGoogle Scholar
• 80 Wadhwa D, Fallah-Rad N, Grenier D et al. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res. Treat. 117(2), 357–364 (2009).
  Medline CASGoogle Scholar
• 81 Fallah-Rad N, Walker JR, Wassef A et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J. Am. Coll. Cardiol. 57(22), 2263–2270 (2011).
  Medline CASGoogle Scholar
• 82 Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J. Cardiovasc. Magn. Reson. 10, 5 (2008).
  MedlineGoogle Scholar
• 83 Neilan TG, Coelho-Filho OR, Pena-Herrera D et al. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Am. J. Cardiol. 110(11), 1679–1686 (2012).
  Medline CASGoogle Scholar
• 84 Drafts BC, Twomley KM, D'agostino R Jr et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc. Imaging 6(8), 877–885 (2013).
  MedlineGoogle Scholar
• 85 Neilan TG, Coelho-Filho OR, Shah RV et al. Myocardial extracellular volume by cardiac magnetic resonance imaging in patients treated with anthracycline-based chemotherapy. Am. J. Cardiol. 111(5), 717–722 (2013).
  Medline CASGoogle Scholar
• 86 Tham EB, Haykowsky MJ, Chow K et al. Diffuse myocardial fibrosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: relationship to exercise capacity, cumulative dose and remodeling. J. Cardiovasc. Magn. Reson. 15, 48 (2013).
  MedlineGoogle Scholar
• 87 Estorch M, Carrio I, Berna L et al. Indium-111-antimyosin scintigraphy after doxorubicin therapy in patients with advanced breast cancer. J. Nucl. Med. 31(12), 1965–1969 (1990).
  Medline CASGoogle Scholar
• 88 Carrio I, Lopez-Pousa A, Estorch M et al. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies. J. Nucl. Med. 34(9), 1503–1507 (1993).
  Medline CASGoogle Scholar
• 89 Carrio I, Estorch M, Berna L, Lopez-Pousa J, Tabernero J, Torres G. Indium-111-antimyosin and iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J. Nucl. Med. 36(11), 2044–2049 (1995).
  Medline CASGoogle Scholar
• 90 Valdes Olmos RA, Carrio I, Hoefnagel CA et al. High sensitivity of radiolabelled antimyosin scintigraphy in assessing anthracycline related early myocyte damage preceding cardiac dysfunction. Nucl. Med. Commun. 23(9), 871–877 (2002).
  Medline CASGoogle Scholar
• 91 Olmos RA, Ten Bokkel Huinink WW, Ten Hoeve RF et al. Assessment of anthracycline-related myocardial adrenergic derangement by [123I]metaiodobenzylguanidine scintigraphy. Eur. J. Cancer 31A(1), 26–31 (1995).
  MedlineGoogle Scholar
• 92 Lakoski SG, Barlow CE, Koelwyn GJ et al. The influence of adjuvant therapy on cardiorespiratory fitness in early-stage breast cancer seven years after diagnosis: the Cooper Center Longitudinal Study. Breast Cancer Res. Treat. 138(3), 909–916 (2013).
  Medline CASGoogle Scholar
• 93 Khouri MG, Hornsby WE, Risum N et al. Utility of 3-dimensional standardizecardiography, global longitudinal strain, and exercise stress standardizecardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy. Breast Cancer Res. Treat. 143(3), 531–539 (2014).
  Medline CASGoogle Scholar
• 94 Mckillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am. Heart J. 106(5 Pt 1), 1048–1056 (1983).
  Medline CASGoogle Scholar
• 95 Civelli M, Cardinale D, Martinoni A et al. Early reduction in left ventricular contractile reserve detected by dobutamine stress standardize predicts high-dose chemotherapy-induced cardiac toxicity. Int. J. Cardiol. 111(1), 120–126 (2006).
  MedlineGoogle Scholar
• 96 Smibert E, Carlin JB, Vidmar S, Wilkinson LC, Newton M, Weintraub RG. Exercise standardizecardiography reflects cumulative anthracycline exposure during childhood. Pediatr. Blood Cancer 42(7), 556–562 (2004).
  MedlineGoogle Scholar
• 97 De Souza AM, Potts JE, Potts MT et al. A stress standardizecardiography study of cardiac function during progressive exercise in pediatric oncology patients treated with anthracyclines. Pediatr. Blood Cancer 49(1), 56–64 (2007).
  MedlineGoogle Scholar
• 98 Guimaraes-Filho FV, Tan DM, Braga JC, Rodrigues A, Waib PH, Matsubara BB. Ventricular systolic reserve in asymptomatic children previously treated with low doses of anthracyclines: a longitudinal, prospective exercise standardizecardiography study. Pediatr. Blood Cancer 59(3), 548–552 (2012).
  MedlineGoogle Scholar
• 99 Sieswerda E, Kremer LC, Vidmar S et al. Exercise standardizecardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study. Pediatr. Blood Cancer 54(4), 579–584 (2010).
  MedlineGoogle Scholar
• 100 Klewer SE, Goldberg SJ, Donnerstein RL, Berg RA, Hutter JJ Jr. Dobutamine stress standardizecardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. J. Am. Coll. Cardiol. 19(2), 394–401 (1992).
  Medline CASGoogle Scholar
• 101 Lanzarini L, Bossi G, Laudisa ML, Klersy C, Arico M. Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines. Am. Heart J. 140(2), 315–323 (2000).
  Medline CASGoogle Scholar
• 102 Gupta S, Rohatgi A, Ayers CR et al. Cardiorespiratory fitness and classification of risk of cardiovascular disease mortality. Circulation 123(13), 1377–1383 (2011).
  MedlineGoogle Scholar
• 103 Gulati M, Pandey DK, Arnsdorf MF et al. Exercise capacity and the risk of death in women: the St James Women Take Heart Project. Circulation 108(13), 1554–1559 (2003).
  MedlineGoogle Scholar
• 104 Jones LW, Watson D, Herndon JE 2nd et al. Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer. Cancer 116(20), 4825–4832 (2010).
  MedlineGoogle Scholar
• 105 Jones LW, Hornsby WE, Goetzinger A et al. Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer. Lung Cancer 76(2), 248–252 (2012).
  MedlineGoogle Scholar
• 106 Jones LW, Courneya KS, Mackey JR et al. Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum. J. Clin. Oncol. 30(20), 2530–2537 (2012).• Demonstrates that breast cancer survivors have significantly impaired aerobic capacity despite normal resting LVEF.
  MedlineGoogle Scholar
• 107 Cardinale D, Sandri MT. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog. Cardiovasc. Dis. 53(2), 121–129 (2010).
  Medline CASGoogle Scholar
• 108 Thigpen SC, Geraci SA. Prediction of anthracycline-induced left ventricular dysfunction by cardiac troponins. South. Med. J. 105(12), 659–664 (2012).
  MedlineGoogle Scholar
• 109 Cardinale D, Sandri MT, Martinoni A et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J. Am. Coll. Cardiol. 36(2), 517–522 (2000).
  Medline CASGoogle Scholar
• 110 Cardinale D, Sandri MT, Colombo A et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109(22), 2749–2754 (2004).
  Medline CASGoogle Scholar
• 111 Cardinale D, Sandri MT, Martinoni A et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann. Oncol. 13(5), 710–715 (2002).
  Medline CASGoogle Scholar
• 112 Sandri MT, Cardinale D, Zorzino L et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin. Chem. 49(2), 248–252 (2003).
  Medline CASGoogle Scholar
• 113 Cardinale D, Colombo A, Torrisi R et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J. Clin. Oncol. 28(25), 3910–3916 (2010).
  Medline CASGoogle Scholar
• 114 Morris PG, Chen C, Steingart R et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin. Cancer Res. 17(10), 3490–3499 (2011).
  Medline CASGoogle Scholar
• 115 Ky B, Putt M, Sawaya H et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J. Am. Coll. Cardiol. 63(8), 809–816 (2014).
  Medline CASGoogle Scholar